替格瑞洛升高腺苷浓度引起的生物学效应和不良反应研究进展

发布时间：2018-06-30 20:28

  本文选题：急性冠状动脉综合征 + 替格瑞洛　； 参考：《中国新药与临床杂志》2016年09期

【摘要】：替格瑞洛是一种新型的具有多效性的P_2Y_(12)受体抑制剂,能够抑制腺苷二磷酸诱导的血小板聚集。目前的研究发现替格瑞洛还能影响腺苷的浓度,其可能的机制是通过抑制平衡型核苷转运体1来抑制红细胞对腺苷的摄取,增加胞外腺苷浓度。相关的研究提示,在使用替格瑞洛时,呼吸困难、心动过缓等不良反应的发生也与腺苷浓度的增加相关。本文将对替格瑞洛对腺苷浓度的影响以及所引起的生物学效应和不良反应进行综述。
[Abstract]:Tigrilol is a novel multipotent PSP 2 Y12 receptor inhibitor which can inhibit platelet aggregation induced by adenosine diphosphate (ADP). It has been found that tigrilol can also affect the concentration of adenosine by inhibiting the uptake of adenosine in erythrocytes and increasing the concentration of extracellular adenosine by inhibiting balanced nucleoside transporter 1. Related studies suggest that adverse reactions such as dyspnea and bradycardia are also associated with increased adenosine concentration in tigrillo. This article reviews the effects of tigrilol on adenosine concentration, biological effects and adverse reactions.
【作者单位】： 复旦大学附属中山医院药剂科;
【分类号】：R973.2
，

本文编号：2086756